News / Press Release

Clinical Infomatics News: What To Know Before Pairing Drugs With A Checkpoint Inhibitor

Clinical Informatics News / October 29, 2018

These days, there are thousands of clinical trials, and many drug makers rush to pair their drugs with checkpoint inhibitors. The thing is, often times this logic isn’t based on a good scientific story, leading to many drugs failing and leaving many patients with inferior, nonscientific regimens, which isn’t fair to them.

It’s not that combination strategies can’t work—it’s just that such pairings must be thoroughly vetted to ensure they work in the clinic. How to accomplish that? By asking a series of questions beforehand to help determine if a drug is likely to work well in combination with a checkpoint inhibitor, according to TD2 President and CEO Stephen Gately. Before jumping on the “combination bandwagon,” discover how to uncover the goals, opportunities and challenges of combination-based research in Stephen’s recent article for Clinical Informatics News.

For more information, please contact
About Translational Drug Development (TD2)

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

About TD2

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

Contact
Tara Franks
602-358-8322
Get free tips, tools and resources by subscribing to the TD2 Newsletter: